#ASH22: Pirtobrutinib emerges as an option for Richter’s Transformation
Pharmaceutical Technology
DECEMBER 11, 2022
Due to the rarity of the disease, no FDA-approved therapy exists specifically for RT, and these patients are treated using regimens derived from the DLBCL treatment paradigm and other small-scale clinical trials. In the pirtobrutinib safety cohort, only 2.6% of patients discontinued treatment due to adverse events.
Let's personalize your content